S&P Futures
4,215.75 +6.00 (+0.14%) Dow Futures
33,342.00 +38.00 (+0.11%) Nasdaq Futures
13,341.50 +30.25 (+0.23%) Russell 2000 Futures
1,980.30 +4.00 (+0.20%) Crude Oil
93.88 -0.46 (-0.49%) Gold
1,807.50 +0.30 (+0.02%)
AstraZeneca PLC (AZN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 65.83 |
| Open | 65.05 |
| Bid | 0.00 x 3100 |
| Ask | 0.00 x 3000 |
| Day's Range | 64.26 - 65.05 |
| 52 Week Range | 53.63 - 71.70 |
| Volume | |
| Avg. Volume | 6,272,338 |
| Market Cap | 200.349B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.45 (2.20%) |
| Ex-Dividend Date | Aug 11, 2022 |
| 1y Target Est | 73.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AZN
Related Research
- Astrazeneca PLCWeekly Stock ListDividends are supposed to lend stability to a portfolio. However, U.S.-based income investors have experienced a high degree of volatility in recent years, as the Federal Reserve since 2018 has embarked on two campaigns to raise interest rates, sandwiched around a desperate program that lowered the federal funds rate to zero in order to help the economy recover from the pandemic. The endless speculation over the direction of rates has created market-timing headaches for equity income investors. They have endured wide swings in prices for rate-sensitive equity sectors such as Utilities, REITs and MLPs. In our view, investing in international income stocks is one way to increase portfolio diversification while reducing sensitivity to volatile U.S interest rates. Investing in overseas stocks carries its own set of risks, including the impact of currency exchange and geopolitical turmoil. But there are also a number of positives in this asset class for U.S. investors, including a wide selection, robust industry diversification, higher yields, and lower valuations. Argus has recently boosted its global coverage, and recommends the following international dividend stocks. Note this list of 25 companies offers exposure to eight of the 11 major sectors. The list includes companies from 10 countries.RatingFair ValueEconomic Moat4 days agoArgus Research
- Benzinga
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) decided to discontinue the development of oral SERD asset ZN-c5 and EGFR inhibitor ZN-e4 following the completion of existing clinical trials. The company will focus its capital on developing the WEE1 drug, ZN-c3, and BCL-2 inhibitor, ZN-d5. SVB Leerink says that the decision was not unexpected given the difficulty the SERD class has had demonstrating superiority to aromatase inhibitors in the metastatic settings and the cost needed to pursue developme
- Zacks
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
- Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
AstraZeneca Plc (NASDAQ: AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in non-small cell lung cancer (NSCLC) without actionable genomic alterations. Datopotamab deruxtecan is jointly developed by Daiichi Sankyo (OTC: DSKNY) and AstraZeneca. The interim analysis demonstrated an overall
